About

Visits

Aster R V Hospital

Jp Nagar, Bangalore

CA-37, 24th Main, 1st Phase, J.P.Nagar

₹ 900 Approx.

Enquire Now

Consult Aster R V Hospital

WhatsApp

Services

• Bone Marrow Transplant
• Cancer Treatment
• Chemotherapy
• Chemotherapy Of Haematological Malignancies
• Chemotherapy Of Solid Tumors
• Picc Line Insertion
• Pet Scan
• Oral Cancer Treatment

Specializations

• Oncologist

Reviews

Education

1. MBBS

   Jawaharlal Nehru Medical College, Belgaum

   1999

2. MD - Medicine

   Manipal Academy of Higher Sciences, Manipal

   2002

3. PhD - Medical Sciences

   Hull York Medical School

   2012

4. CCT (Medical Oncology,UK)

   General Medical Council

   2012

5. MRCP

   UK

   2005

Awards

1. PhD by Hull York Medical School, UK

   2013

Experience

1. Lead and Senior Consultant Medical Oncologist

   Aster CMI Hospital, Hebbal, Bangalore

   2018 - 2020

2. Senior Consultant Medical Oncologist

   Health Care Global Enterprises, K. R. Road, Bangalore

   2015 - 2018

3. Consultant Medical Oncologist

   21/01/2013 – 28/07/2015 Consultant Medical Oncologist Queen Elizabeth Hospital, University Hospital Birmingham NHS Trust, Birmingham, UK

   2013 - 2015

Citations

1. Current treatment options for human epidermal growth factor receptor 2-directed therapy in metastatic breast cancer: An Indian perspective

   2018

2. Is EGFR really a therapeutic target in head and neck cancers?

   2019

3. Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker.

   2014

4. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?

   2010

5. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?

   2012

6. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?

   2010

7. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?

   2012

8. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?

   2010

9. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?

   2012

10. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?

    2010

11. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?

    2012

12. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?

    2010

13. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?

    2012

14. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?

    2010

15. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?

    2012

16. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?

    2012

17. PTEN protein expression in malignant pleural mesothelioma.

    2012

18. Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697

    2013

19. Human epidermal growth factor receptor-2 expression in head and neck squamous cell carcinoma: A potential for targeted therapy?

    2016

20. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?

    2010

21. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?

    2012

22. Adjuvant! Online as a decision-making tool in early breast cancer--a UK national survey

    2011

23. Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report

    2011

24. Pre-treatment neutrophil lymphocyte ratio/platelet lymphocyte ratio as surrogate markers of survival in non-metastatic head and neck cancer patients: An observational study

    2017

Memberships

1. General Medical Council (GMC), UK
2. European Society of Medical Oncology (ESMO)
3. Royal College of Physicians (UK)
4. Flims Alumni Club